Progress in Adeno-Associated Virus Type 2 Vector Production: Promises and Prospects for Clinical Use
- 10 October 1999
- journal article
- review article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 10 (15), 2445-2450
- https://doi.org/10.1089/10430349950016799
Abstract
Vectors derived from the human parvovirus AAV-2 (adeno-associated virus type 2) are among the most promising gene delivery vehicles currently being developed. These vectors are not only capable of transducing a large variety of human cell types in vitro and in vivo, but in immunocompetent animal models can establish longterm gene expression without being pathogenic to the recipient. However, a limitation of this vector system with respect to its clinical application has long been the laborious work needed to prepare high-titer and pure AAV-2 vector stocks. A number of improvements to the basic manufacturing protocol have recently been reported that now allow the production of AAV-2 vectors of significantly higher quality and quantity. This article considers the most relevant approaches taken so far, which include modifications to the conventional transfection/infection protocol as well as the development of helper virus-free packaging methods and the establishment of vector producer cell lines. The various novel protocols are discussed, including their advantages and drawbacks, with a particular focus being put on their prospects for clinical use. Despite these advancements, the development of an ideal AAV-2 vector production method fully suiting clinical requirements obviously remains a challenging issue.Keywords
This publication has 44 references indexed in Scilit:
- High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and CapGene Therapy, 1999
- Recombinant adeno-associated virus purification using novel methods improves infectious titer and yieldGene Therapy, 1999
- Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirusGene Therapy, 1999
- Novel Tools for Production and Purification of Recombinant Adenoassociated Virus VectorsHuman Gene Therapy, 1998
- High-Titer Adeno-Associated Viral Vectors from a Rep/Cap Cell Line and Hybrid Shuttle VirusHuman Gene Therapy, 1998
- Factors Influencing Recombinant Adeno-Associated Virus ProductionHuman Gene Therapy, 1998
- Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophiliaGene Therapy, 1998
- HSV/AAV Hybrid Amplicon Vectors Extend Transgene Expression in Human Glioma CellsHuman Gene Therapy, 1997
- Replication of rep-cap Genes Is Essential for the High-Efficiency Production of Recombinant AAVHuman Gene Therapy, 1997
- Cell Lines for the Production of Recombinant Adeno-Associated VirusHuman Gene Therapy, 1995